T2 Biosystems CS (TTOO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.1144 -0.0006 (-0.52%) 04/28/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.1144 unch (unch) 15:54 ET
for Mon, Apr 28th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Cash Flows From Operating Activities | |||||
Net Income | -50,077 | -62,003 | -49,241 | -46,798 | -59,006 |
Depreciation Amortization | 859 | 1,047 | 2,690 | 3,228 | 3,642 |
Accounts receivable | 743 | 2,971 | -35 | -2,274 | -1,039 |
Accounts payable and accrued liabilities | 231 | -1,566 | 761 | -1,652 | 2,960 |
Other Working Capital | -4,042 | -503 | -2,171 | -6,538 | 1,858 |
Other Operating Activity | 4,150 | 9,425 | 9,122 | 10,819 | 6,224 |
Operating Cash Flow | $-48,136 | $-50,629 | $-38,874 | $-43,215 | $-45,361 |
Cash Flows From Investing Activities | |||||
Change In Deposits | N/A | N/A | 25,251 | -35,461 | N/A |
PPE Investments | -192 | -339 | -460 | -800 | -761 |
Sale Of Investment | N/A | 9,998 | N/A | N/A | N/A |
Investing Cash Flow | $-192 | $9,659 | $24,791 | $-36,261 | $-761 |
Cash Flows From Financing Activities | |||||
Debt Repayment | N/A | N/A | N/A | N/A | -882 |
Common Stock Issued | 52,750 | 29,327 | 20,535 | 85,607 | 7,232 |
Other Financing Activity | -62 | -273 | 0 | 0 | 0 |
Financing Cash Flow | $52,688 | $29,054 | $20,535 | $85,607 | $6,350 |
Beginning Cash Position | 11,880 | 23,796 | 17,344 | 11,213 | 50,985 |
End Cash Position | 16,240 | 11,880 | 23,796 | 17,344 | 11,213 |
Net Cash Flow | $4,360 | $-11,916 | $6,452 | $6,131 | $-39,772 |
Free Cash Flow | |||||
Operating Cash Flow | -48,136 | -50,629 | -38,874 | -43,215 | -45,361 |
Capital Expenditure | -192 | -339 | -460 | -804 | -761 |
Free Cash Flow | -48,328 | -50,968 | -39,334 | -44,019 | -46,122 |